Loading...
Market
Impact on Pfizer's antibiotics market share by end of 2025
5
Resolution / Starting Odds
Increase significantly • 33%
Increase slightly • 33%
No change • 34%
Industry analytics and Pfizer's market share reports
Story
EU Approves Pfizer's Emblaveo for Gram-Negative Bacterial Infections
Apr 22, 2024, 12:41 PM
The European Commission has approved Pfizer's new antibiotic, Emblaveo (aztreonam-avibactam), for treating multidrug-resistant infections caused by Gram-negative bacteria, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). This approval, endorsed by the European Medicines Agency, addresses the critical need for treatments against severe infections with limited options.
View original story
Similar markets
Market share decreases • 33%
Market share remains stable • 33%
Market share increases • 34%
Increase by up to 5% • 25%
Increase by 5% to 10% • 25%
Increase by 10% to 15% • 25%
Increase by more than 15% • 25%
Ozempic gains over 30% market share • 25%
Ozempic gains 10-30% market share • 25%
Ozempic gains less than 10% market share • 25%
Ozempic loses market share • 25%
Significant gain in market share • 33%
Moderate gain in market share • 34%
No significant change in market share • 33%
Increase in Market Share • 33%
Decrease in Market Share • 33%
No Change in Market Share • 34%
Increase in Market Share • 25%
No Significant Change • 25%
Decrease in Market Share • 25%
Significant Loss in Market Share • 25%
Increases significantly • 25%
Increases slightly • 25%
Remains stable • 25%
Decreases • 25%
Increased Moderna market share • 33%
No significant change • 34%
Decreased Pfizer/BioNTech market share • 33%
Increase more than 5% • 25%
Increase up to 5% • 25%
No change • 25%
Decrease • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Increase in market share • 33%
No change • 33%
Decrease in market share • 34%
Increase significantly • 25%
Increase moderately • 25%
No significant change • 25%
Decrease • 25%